Recent Reports

  • Pharmaceuticals – Three therapies to support growth

    Edmund Xue | Phillip Securities Research Pte Ltd | Mar 22, 2019
    • We expect an 18.6% CAGR for the oncology therapeutic segment, which is the key lever of growth along with anti-infection and endocrinology.
    • The average operating margin for big pharma increased by 29.2% YoY in Q4 2018. We expect strong operating margins looking forward despite pricing pressures. 
    • There is a positive outlook for the R&D pipeline for pharma, which will help to weather LOE and biosimilar headwinds.
    • U.S. and pharmerging markets, especially China, will lead growth for the global pharma market.
    • We are EQUAL-WEIGHT on the pharma sector. Our preferred stocks are Eli Lilly (LLY) for its expanding pipeline and solid product launches, and Merck & Co (MRK) for its favourable margin expansion opportunities with its Keytruda (oncology) products.
  • Singapore Exchange Limited – Derivatives growth the slowest in almost two years

    Tin Min Ying | Phillip Securities Research Pte Ltd | Mar 19, 2019

    Recommendation: ACCUMULATE (Downgrade), Last Close Price: S$7.31

    Target Price: S$8.17 (previous TP: S$8.36), Analyst: Tin Min Ying

    • HKEX announced the launch of futures contracts on MSCI China A Index.
    • SGX’s February Derivatives Daily Average Volume (DDAV) growth was flat at 1.4% YoY, the lowest in almost two years.
    • SGX’s derivatives business accounts for c.49% of total revenue in 6M19.
    • We downgrade to Accumulate at a lower TP of S$8.17 (previously S$8.36) as lowered our FY19e earnings by 2%. We peg our TP to 23.2x P/E, at SGX’s 5-year mean.
  • Singapore Coal Monthly – Indonesian coal to see a new opportunity

    Chen Guangzhi | Phillip Securities Research Pte Ltd | Mar 18, 2019

    Recommendation: OVERWEIGHT, Analyst: Chen Guangzhi

    • China restricted Australian coal imports
    • Approval for the resumption of work in coal mines in Yulin City in Shannxi
    • Demand for Indonesian thermal coal heats up
  • Y Ventures Group Ltd – More controlled expansion

    Paul Chew | Phillip Securities Research Pte Ltd | Mar 8, 2019
    • Results were below expectations due to poor sales of non-book products, weaker gross margins, higher operating expenses and write-offs in inventory and bad debts.
    • 80% of FY18 revenue is from the sale of books and YVEN has expanded their publishing principals from 1 to 8.
    • A major change is strategy is to faster monetize their data analytics capabilities through the sale of services.
    • We lowered FY19e earnings to marginal profitability. Any turnaround in profits is earmarked in FY20e. Our target price of S$0.16 will be based off FY20e earnings and PE of 30x. This is priced against other e-retailer comparables.


  • Banyan Tree Holdings Limited – Gathering momentum in management contracts

    Tara Wong | Phillip Securities Research Pte Ltd | Mar 8, 2019
    • PATMI met expectations excluding the surge in effective tax due to higher withholding tax and under provision of taxes in prior years.
    • Sizable uptick in property sales from Phuket. Secured a record 28 new hotel management contracts in 2018, with a pipeline of 53 hotel openings from 2019 to 2022.
    • Hotel investments segment took a hit from Thailand underperformance and Seychelles deconsolidation effect. Decline in forward bookings, dragged down largely by Thailand.
    • Long-term growth catalysts remain intact. Focus would be the continued build-up in fee-based income and property sales.
    • Maintain ACCUMULATE with adjusted target price of S$0.76 (prev. S$0.73).
  • See All

Technical Pulse

See All

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!